74 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic … CD19 CAR T-Cell Therapy (GLPG5201) in Relapsed/Refractory Chronic Lymphocytic Leukemia Including Richter Transformation: Results from the Phase 1
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
achievements in 2023 Corporate and Operational Performance 2023 Oncology portfolio GLPG5201 (CD19 CAR-T) in relapsed/refractory chronic lymphocytic … in development as of the date of the publication of this report: NHL, myeloma; non- Hodgkin SLE, systemic lymphoma; lupus erythematosus; CLL, chronic
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
) in relapsed/refractory chronic lymphocytic leukemia (rrCLL) and Richter transformation (RT) (cut-off date: 6 September 2023)Patient recruitment of the Phase 1
6-K
EX-99.1
GLPG
Galapagos NV
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
chronic lymphocytic leukemia (rrCLL) and patients with Richter transformation (RT). Further, previously disclosed safety, efficacy and feasibility data …
Galapagos abstracts
Seven-Day Vein-to-Vein Point-of-Care–Manufactured GLPG5201 Anti-CD19 CAR-T Cells Display Early Phenotype in Relapsed/Refractory Chronic
6-K
EX-99.1
0d7 gt451b3e
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
zoxsv8th2btt3 sn
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
46m5aob6fslxe2vkpwi
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
ytobu 4jjwm
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
5imu1xdi2wc8 nlfnyk
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
hd1emccw1aox
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
fc2fl4 sm
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
ik5kibch8fg10
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
3pna75m1xke5tfiyqvco
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
h6h6 okv0
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
afkt6mcqf8hqbmsb l6z
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.1
ozw6rmvp2c3f7a
9 Nov 22
Current report (foreign)
4:05pm
6-K
EX-99.1
0kccmho
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
ttu2tl
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
sqysstnv9 63lx81wyiz
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm